Cargando…

301. Risk of Virologic Failure with Antiretroviral Switches in HIV/HCV Co-infections

BACKGROUND: Direct-acting antivirals (DAA) and antiretroviral (ARV) medications pose treatment challenges in HIV/HCV co-infection. Management of contraindicated combinations varies across practices. ARV switches may increase the risk of HIV virologic and treatment failure, and has been reported to i...

Descripción completa

Detalles Bibliográficos
Autores principales: Mosquera, Diana M, Wilder, Julius, Ellis, Alicia, Naggie, Susanna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810675/
http://dx.doi.org/10.1093/ofid/ofz360.2506
_version_ 1783462306773991424
author Mosquera, Diana M
Wilder, Julius
Ellis, Alicia
Naggie, Susanna
author_facet Mosquera, Diana M
Wilder, Julius
Ellis, Alicia
Naggie, Susanna
author_sort Mosquera, Diana M
collection PubMed
description BACKGROUND: Direct-acting antivirals (DAA) and antiretroviral (ARV) medications pose treatment challenges in HIV/HCV co-infection. Management of contraindicated combinations varies across practices. ARV switches may increase the risk of HIV virologic and treatment failure, and has been reported to increase the risk of DAA treatment failure. This analysis assesses how switches in ARV regimen impacts treatment outcomes in HIV/HCV co-infection. METHODS: This retrospective cohort study includes patients 18 years and older with stable HIV/HCV co-infection (HIV RNA<50 for ≥6 months) who received DAA HCV therapy. Data were obtained using the Centers for AIDS Research Network of Integrated Clinical Systems. The “ARV switch” cohort is defined as patients undergoing a switch in ARV regimen within 6 months prior to DAA treatment. The “no ARV switch” cohort was defined as patients without a change in ARV during the same time period. The primary outcome is HIV treatment failure which is a composite endpoint including HIV virologic failure (defined as confirmed loss of HIV viral suppression), discontinuation/change of ARV regimen, progression to AIDS, or death. We compared baseline characteristics, the proportion of patients free of HIV treatment failure, free of HIV virologic failure, and that achieved sustained viral response (SVR) at 12 and 24 weeks after DAA treatment among ARV switch and no ARV switch groups. RESULTS: Of the 256 patients, 63/256 (25%) underwent an ARV switch (Table 1). At baseline, the most common regimen in the ARV switch group was protease inhibitor (PI)-based while for the no ARV switch group, it was an integrase strand transfer inhibitor (INSTI)-based regimen. HIV/HCV transmission risk factors, HCV genotype, and AST/ALT were similar among the two groups (Table 1). The proportion with HIV treatment and virologic failure, and the proportion achieving SVR12/24 were similar among the ARV switch and no ARV switch groups. CONCLUSION: HIV treatment and virologic failure, and SVR12/24 were not different among patients who did or did not undergo a switch in their ARV regimen prior to DAA treatment. This suggests that switches in the ARV regimen for DAA treatment of HCV do not negatively impact HIV or HCV outcomes among patients with HIV/HCV Coinfection. [Image: see text] DISCLOSURES: All authors: No reported disclosures.
format Online
Article
Text
id pubmed-6810675
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-68106752019-10-28 301. Risk of Virologic Failure with Antiretroviral Switches in HIV/HCV Co-infections Mosquera, Diana M Wilder, Julius Ellis, Alicia Naggie, Susanna Open Forum Infect Dis Abstracts BACKGROUND: Direct-acting antivirals (DAA) and antiretroviral (ARV) medications pose treatment challenges in HIV/HCV co-infection. Management of contraindicated combinations varies across practices. ARV switches may increase the risk of HIV virologic and treatment failure, and has been reported to increase the risk of DAA treatment failure. This analysis assesses how switches in ARV regimen impacts treatment outcomes in HIV/HCV co-infection. METHODS: This retrospective cohort study includes patients 18 years and older with stable HIV/HCV co-infection (HIV RNA<50 for ≥6 months) who received DAA HCV therapy. Data were obtained using the Centers for AIDS Research Network of Integrated Clinical Systems. The “ARV switch” cohort is defined as patients undergoing a switch in ARV regimen within 6 months prior to DAA treatment. The “no ARV switch” cohort was defined as patients without a change in ARV during the same time period. The primary outcome is HIV treatment failure which is a composite endpoint including HIV virologic failure (defined as confirmed loss of HIV viral suppression), discontinuation/change of ARV regimen, progression to AIDS, or death. We compared baseline characteristics, the proportion of patients free of HIV treatment failure, free of HIV virologic failure, and that achieved sustained viral response (SVR) at 12 and 24 weeks after DAA treatment among ARV switch and no ARV switch groups. RESULTS: Of the 256 patients, 63/256 (25%) underwent an ARV switch (Table 1). At baseline, the most common regimen in the ARV switch group was protease inhibitor (PI)-based while for the no ARV switch group, it was an integrase strand transfer inhibitor (INSTI)-based regimen. HIV/HCV transmission risk factors, HCV genotype, and AST/ALT were similar among the two groups (Table 1). The proportion with HIV treatment and virologic failure, and the proportion achieving SVR12/24 were similar among the ARV switch and no ARV switch groups. CONCLUSION: HIV treatment and virologic failure, and SVR12/24 were not different among patients who did or did not undergo a switch in their ARV regimen prior to DAA treatment. This suggests that switches in the ARV regimen for DAA treatment of HCV do not negatively impact HIV or HCV outcomes among patients with HIV/HCV Coinfection. [Image: see text] DISCLOSURES: All authors: No reported disclosures. Oxford University Press 2019-10-23 /pmc/articles/PMC6810675/ http://dx.doi.org/10.1093/ofid/ofz360.2506 Text en © The Author(s) 2019. Published by Oxford University Press on behalf of Infectious Diseases Society of America. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Abstracts
Mosquera, Diana M
Wilder, Julius
Ellis, Alicia
Naggie, Susanna
301. Risk of Virologic Failure with Antiretroviral Switches in HIV/HCV Co-infections
title 301. Risk of Virologic Failure with Antiretroviral Switches in HIV/HCV Co-infections
title_full 301. Risk of Virologic Failure with Antiretroviral Switches in HIV/HCV Co-infections
title_fullStr 301. Risk of Virologic Failure with Antiretroviral Switches in HIV/HCV Co-infections
title_full_unstemmed 301. Risk of Virologic Failure with Antiretroviral Switches in HIV/HCV Co-infections
title_short 301. Risk of Virologic Failure with Antiretroviral Switches in HIV/HCV Co-infections
title_sort 301. risk of virologic failure with antiretroviral switches in hiv/hcv co-infections
topic Abstracts
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6810675/
http://dx.doi.org/10.1093/ofid/ofz360.2506
work_keys_str_mv AT mosqueradianam 301riskofvirologicfailurewithantiretroviralswitchesinhivhcvcoinfections
AT wilderjulius 301riskofvirologicfailurewithantiretroviralswitchesinhivhcvcoinfections
AT ellisalicia 301riskofvirologicfailurewithantiretroviralswitchesinhivhcvcoinfections
AT naggiesusanna 301riskofvirologicfailurewithantiretroviralswitchesinhivhcvcoinfections